Silvia W. Ling

Liverpool, NSW, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Review of the first on-body injector (OBI) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myeloma.

Review of the first on-body injector (OBI) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myeloma.

Journal: Expert opinion on drug delivery

Published: April 13, 2026

From Spatial Heterogeneity to Real-Time Monitoring: Liquid Biopsy for Genomic Profiling and MRD Assessment in Multiple Myeloma.

From Spatial Heterogeneity to Real-Time Monitoring: Liquid Biopsy for Genomic Profiling and MRD Assessment in Multiple Myeloma.

Journal: Cancers

Published: April 02, 2026

Circulating Plasma Cells as a Minimally Invasive Adjunct to Bone Marrow Aspirates for Genetic Analysis of ER Stress and Autophagy in Multiple Myeloma: A Feasibility Study.

Circulating Plasma Cells as a Minimally Invasive Adjunct to Bone Marrow Aspirates for Genetic Analysis of ER Stress and Autophagy in Multiple Myeloma: A Feasibility Study.

Journal: Biomedicines

Published: December 12, 2025

Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.

Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 10, 2025

Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant-Ineligible Newly Diagnosed Myeloma: An Australian Real-World, Multicenter Study.

Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant-Ineligible Newly Diagnosed Myeloma: An Australian Real-World, Multicenter Study.

Journal: Asia-Pacific journal of clinical oncology

Published: November 11, 2025

Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

Journal: Internal medicine journal

Published: August 27, 2025

Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.

Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 08, 2025

Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.

Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 03, 2025

Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs.

Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs.

Journal: Nature communications

Published: September 26, 2024

A single-day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies.

A single-day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies.

Journal: European journal of haematology

Published: April 22, 2024

The use of cell free DNA (cfDNA) for mutational screening of multiple myeloma.

The use of cell free DNA (cfDNA) for mutational screening of multiple myeloma.

Journal: Leukemia research reports

Published: July 29, 2023

Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA.

Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA.

Journal: Blood cancer journal

Published: May 02, 2023

Showing 1-12 of 23

Last Updated: 09/26/2026